Association of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individuals.
dendritic cell-based therapeutic HIV-1 vaccine
differential gene expression
gene set enrichment analysis
mRNA
miRNA
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
19 Jul 2021
19 Jul 2021
Historique:
received:
29
05
2021
revised:
05
07
2021
accepted:
14
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Systems vaccinology has seldomly been used in therapeutic HIV-1 vaccine research. Our aim was to identify early gene 'signatures' that predicted virus load control after analytical therapy interruption (ATI) in participants of a dendritic cell-based HIV-1 vaccine trial (DCV2). mRNA and miRNA were extracted from frozen post-vaccination PBMC samples; gene expression was determined by microarray method. In gene set enrichment analysis, responders showed an up-regulation of 14 gene sets (TNF-alpha/NFkB pathway, inflammatory response, the complement system, Il6 and Il2 JAK-STAT signaling, among others) and a down-regulation of 7 gene sets (such as E2F targets or interferon alpha response). The expression of genes regulated by three (miR-223-3p, miR-1183 and miR-8063) of the 9 differentially expressed miRNAs was significantly down-regulated in responders. The deregulation of certain gene sets related to inflammatory processes seems fundamental for viral control, and certain miRNAs may be important in fine-tuning these processes.
Identifiants
pubmed: 34358215
pii: vaccines9070799
doi: 10.3390/vaccines9070799
pmc: PMC8310264
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European CommissionH2020- SC1-2016-RTD
ID : 731626
Organisme : Ministerio de Economía y Competitividad
ID : SAF2015-66193-R
Organisme : Ministerio de Economía y Competitividad
ID : RTI2018-096309-B-I00
Organisme : Fondo de Investigación Sanitaria (FIS)
ID : PI15/00480
Organisme : Fondo de Investigación Sanitaria (FIS)
ID : AC16/00051
Organisme : Fondo de Investigación Sanitaria (FIS)
ID : PI18/ 00699
Organisme : amfAR, The Foundation for AIDS Research
ID : 108821-55-RGRL
Organisme : Spanish AIDS Research Network
ID : RD16/0025/0002
Organisme : CERCA Program / Generalitat de Catalunya
ID : SGR 615
Références
Nat Immunol. 2011 Jul 10;12(8):786-95
pubmed: 21743478
Vaccine. 2018 Aug 28;36(36):5350-5357
pubmed: 28774561
Nucleic Acids Res. 2014;42(17):e133
pubmed: 25063298
Genome Biol. 2008;9(2):R26
pubmed: 18248669
Vaccine. 2015 Jun 9;33(25):2922-9
pubmed: 25913415
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404856
Front Immunol. 2019 Apr 24;10:874
pubmed: 31105698
Nat Commun. 2018 Mar 23;9(1):1212
pubmed: 29572470
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):11-9
pubmed: 27171739
Antiviral Res. 2013 Nov;100(2):420-8
pubmed: 23933117
Clin Chem. 2013 Aug;59(8):1175-86
pubmed: 23592504
Sci Transl Med. 2013 Jan 2;5(166):166ra2
pubmed: 23283367
J Intern Med. 2013 Sep;274(3):215-26
pubmed: 23772809
EBioMedicine. 2019 May;43:307-316
pubmed: 31005516
Nat Immunol. 2009 Jan;10(1):116-125
pubmed: 19029902
Nat Med. 2007 Oct;13(10):1241-7
pubmed: 17906637
Mol Cell Ther. 2014 Apr 03;2:11
pubmed: 26056580
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
AIDS Res Hum Retroviruses. 2008 Aug;24(8):1047-66
pubmed: 18724805
Immunology. 2019 Jan;156(1):33-46
pubmed: 30317555
Genome Biol. 2004;5(10):R80
pubmed: 15461798
PLoS One. 2014 May 14;9(5):e95920
pubmed: 24828336
Cell Immunol. 2016 May;303:1-6
pubmed: 27129807
Science. 2007 Dec 21;318(5858):1931-4
pubmed: 18048652
PLoS One. 2014 Sep 16;9(9):e106360
pubmed: 25225963
Expert Rev Vaccines. 2017 Jun;16(6):587-600
pubmed: 28431490
Nat Commun. 2016 Jan 08;7:10369
pubmed: 26742691
Sci Rep. 2016 Jun 20;6:28279
pubmed: 27320691
PLoS One. 2016 May 12;11(5):e0155245
pubmed: 27171002